Maridebart cafraglutide

Maridebart cafraglutide
Clinical data
Other names	AMG 133
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2760218-55-9;
UNII	Z24U3U73HN;

Maridebart cafraglutide (AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor and an antagonist of the GIPR. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.^[1]^[2]^[3]

References

↑ Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.
↑ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.
↑ Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.

[2] Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.

[3] Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.

[1]

[2]

[3]